微芯生物(688321) - 2025 Q2 - 季度业绩预告

Chipscreen Biosciences 2025 Semi-Annual Performance Forecast The company expects significant growth and a turnaround to profitability in H1 2025, with revenue projected to increase by 35% to approximately RMB 407.29 million, and net profit attributable to shareholders by 173% to approximately RMB 30.06 million Current Period Performance Forecast The company anticipates substantial year-on-year growth and a return to profitability for its key financial metrics in the first half of 2025 Performance Forecast Period This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The statistical period for this performance forecast is from January 1, 2025, to June 30, 2025[2] Performance Forecast Details Preliminary calculations indicate significant year-on-year growth across revenue, net profit, and non-recurring net profit, with both profit metrics achieving a turnaround to profitability 2025 Semi-Annual Performance Forecast Key Data | Indicator | 2025 Semi-Annual Estimate | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | Approx. RMB 407.29 million | 35% | | Net Profit Attributable to Shareholders | Approx. RMB 30.06 million | 173% | | Non-Recurring Net Profit Attributable to Shareholders | Approx. RMB 21.19 million | 145% | Unaudited Performance Forecast The performance forecast data presented is a preliminary calculation by the company's finance department and has not yet been audited by a certified public accountant - This performance forecast data has not been audited by a certified public accountant[4] Prior Period Performance Review In H1 2024, the company reported RMB 302.16 million in operating revenue, with net profit and non-recurring net profit both in a loss state, providing a baseline for current period improvements 2024 Semi-Annual Performance Data | Indicator | 2024 Semi-Annual | | :--- | :--- | | Operating Revenue | RMB 302.16 million | | Net Profit Attributable to Shareholders | -RMB 41.01 million | | Non-Recurring Net Profit Attributable to Shareholders | -RMB 47.18 million | Primary Reasons for Performance Change The strong performance growth is primarily driven by increased sales of two core products, Chidamide and Seglitaz, with the company achieving profitability in Q2 2025 - Core product sales growth is the main driver of performance improvement - Chidamide: New indication for diffuse large B-cell lymphoma included in the national medical insurance catalog - Seglitaz: Optimized sales strategy, with its unique "diabetes and liver co-management" advantage gaining market recognition[6] - Q2 2025 performance was strong, with revenue expected to grow by 43% year-on-year and 51% quarter-on-quarter, and net profit attributable to shareholders achieving a turnaround to profitability[6] Risk Warning and Other Disclosures The company confirms no significant uncertainties affecting the forecast's accuracy but reminds investors that the data is preliminary and subject to the final semi-annual report - The company states that no significant uncertainties affecting the accuracy of this performance forecast have been identified[7] - Investors are advised that the current forecast data is preliminary, and the specific financial data will be subject to the company's officially disclosed 2025 semi-annual report[7]